Dicot AB (publ) ("Dicot" or the "Company") conducted a rights issue of approximately SEK 20.3 million during the period of September 3 - September 17, 2019 (the "Rights Issue"). In connection to the Rights Issue, the Company also conducted a directed issue of approximately SEK 2 million (the "Overallotment Issue"). The Rights Issue was subscribed with 244 percent and the Overallotment Issue was fully subscribed. In total, 7,790,823 units were issued in the Rights Issue and 779,082 shares were issued in the Overallotment Issue, both at a subscription price of SEK 2.60. Net proceeds from the Rights Issue amounted to SEK 20,281,75, and net proceeds from the Overallotment Issue amounted to SEK 2,025,613.
The Rights Issue and Overallotment Issue have now been registered with the Swedish Companies Registration Office. The last day of trading in paid subscribed units (BTU) is October 16, 2019. The record day for conversion is October 18, 2019, after which BTU will be converted to shares and warrants of series 2019/2020 (TO1).
Shares and warrants issued in the Rights Issue are estimated to be available on subscribers' custody/vp-accounts on October 22, 2019. Shares issued in the Overallotment Issue are estimated to be available on subscribers' custody/vp-accounts the same day.
The first day of trading in warrants of series 2019/2020 is estimated to be October 22, 2019.
Each warrant of series 2019/2020 entitles the holder to subscribe for one (1) new share in Dicot during the subscription period from October 1, 2020 to October 15, 2020. The subscription price for shares using the warrants will correspond to 70 percent of the volume weighted average price of the Company"s shares according to the Spotlight Stock Market official price list for the period from September 14, 2020 through September 25, 2020 but will not be less than SEK 2.60 or higher than SEK 5.20.
Following the Rights Issue and the Overallotment Issue, the Company has 16,360,728 shares and the Company's share capital is SEK 2,045,091.
ISIN-code for shares in Dicot: SE0011178458
ISIN-code for BTU in Dicot: SE0013101276
ISIN-code for TO1 in Dicot: SE0013101250
For further information, please contact:
About Dicot AB
Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients" lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company"s lead product, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. For more information see www.dicot.se.